Verastem Inc
USUSDVerastem Inc (US:VSTM) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site web
- verastem.com
- Secteur
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siège social
- Needham, United States
- PDG
- Robert Forrester
- Employés
- 102
- Fondée
- 2010
- Actions en circulation
- 90.56 M au 2026-08-03
- Flottant
- 70.57 M
- Capitalisation boursière
- 697.34 M USD
- Initiés
- 1.02%
- Investisseurs institutionnels
- 110.92%
- Secteur d'activité (SIC)
- Pharmaceutical Preparations
- ISIN
- US92337C2035
- LEI
- 549300IY0EFBIU8NQC81
Description
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Dividendes
Aucun versement de dividendes n'a été trouvé (vérifié le 09.10.2026). L'entreprise ne verse probablement pas de dividendes.
Actualités de cette semaine
Pas encore d'actualités du site de l'entreprise.
Principaux actionnaires
| Détenteur | Participation | Actions | Date du rapport |
|---|---|---|---|
| Blackrock Inc. | 10.15% | 9.19 M | 2026-06-30 |
| Armistice Capital, LLC | 7.76% | 7.02 M | 2026-06-30 |
| RTW Investments LP | 7.33% | 6.64 M | 2026-06-30 |
| Deep Track Capital, Lp | 6.34% | 5.74 M | 2026-06-30 |
| State Street Corporation | 5.67% | 5.13 M | 2026-06-30 |
| Rosalind Advisors, Inc. | 4.4% | 3.99 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.25% | 3.85 M | 2026-06-30 |
| Nantahala Capital Manage… | 3.96% | 3.58 M | 2026-06-30 |
| SPDR SERIES TRUST-State… | 3.95% | 3.58 M | 2026-08-31 |
| Stonepine Capital Manage… | 3.7% | 3.35 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 3.61% | 3.27 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.1% | 2.81 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.25% | 2.04 M | 2026-08-31 |
| Vanguard Explorer Fund | 1.54% | 1.4 M | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.06% | 960 598 | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.96% | 872 784 | 2026-07-31 |
| Fidelity Covington Trust… | 0.88% | 793 398 | 2026-08-31 |
| iShares Trust-iShares Ru… | 0.83% | 755 883 | 2026-08-31 |
| BlackRock Funds-BlackRoc… | 0.77% | 701 337 | 2026-05-31 |
| PATERSON DANIEL W (Chief… | ≈0.65% | 589 940 | 2026-08-03 |
| VANGUARD HORIZON FUNDS-V… | 0.59% | 536 651 | 2026-06-30 |
| STUGLIK BRIAN M (Directo… | ≈0.15% | 137 147 | 2026-05-21 |
| CALKINS DANIEL (Chief Fi… | ≈0.13% | 118 014 | 2026-09-21 |
| BAILEY MICHAEL P (Direct… | ≈0.12% | 108 000 | 2026-05-21 |
| JOHNSON JOHN H. (Directo… | ≈0.06% | 52 666 | 2026-05-21 |
| KAPUR ANIL (Director) | ≈0.06% | 52 666 | 2026-05-21 |
| ROBERTSON MICHELLE (Dire… | ≈0.06% | 52 666 | 2026-05-21 |
| ROWINSKY ERIC K. (Direct… | ≈0.06% | 52 666 | 2026-05-21 |
| TOLLEFSON KARIN ANNA (Di… | ≈0.06% | 52 666 | 2026-05-21 |
| ROS MATTHEW (Chief Opera… | ≈0.06% | 50 000 | 2025-04-01 |
